Yahoo
NasdaqGS - Nasdaq Real Time Price USD

AngioDynamics, Inc. (ANGO)

12.25 +0.11 (+0.95%)
As of 10:44:03 AM EDT. Market Open.
Trade ANGO on Coinbase
Chart Range Bar
Loading chart for ANGO
  • Previous Close 12.13
  • Open 12.25
  • Bid 8.74 x 200
  • Ask 15.68 x 200
  • Day's Range 12.06 - 12.35
  • 52 Week Range 9.39 - 16.29
  • Volume 69,709
  • Avg. Volume 641,835
  • Market Cap (intraday) 514.957M
  • Beta (5Y Monthly) 0.30
  • PE Ratio (TTM) --
  • EPS (TTM) -0.78
  • Earnings Date (est.) Jan 6, 2027
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 19.75
  • Zacks Rating Bearish

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which include angiographic catheters, guidewires, drainage catheters, and micropuncture kits for use in invasive procedures. In addition, the company provides total abscession drainage catheters for multi-purpose/general and biliary configurations, and nephrostomy options; mini stick MAX Coaxial microintroducer kits and micro-introducer kits; ports; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

www.angiodynamics.com

632

Full Time Employees

May 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ANGO
4.63%
S&P 500 (^GSPC)
12.78%

1-Year Return

ANGO
1.03%
S&P 500 (^GSPC)
12.04%

3-Year Return

ANGO
92.53%
S&P 500 (^GSPC)
87.51%

5-Year Return

ANGO
57.19%
S&P 500 (^GSPC)
67.64%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 80.92M
Earnings -7.1M
Profit Margin -8.77%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
20M
40M
60M
80M
-13.0%
-12.0%
-11.0%
-10.0%
-9.0%
-8.0%

Analyst Insights

View More

Analyst Price Targets

17.00
19.75 Average
12.24 Current
24.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/13/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 19 -> 18

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -10.12%

  • Return on Assets (ttm)

    -5.14%

  • Return on Equity (ttm)

    -19.21%

  • Revenue (ttm)

    325.38M

  • Net Income Avi to Common (ttm)

    -32.94M

  • Diluted EPS (ttm)

    -0.78

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    33.97M

  • Total Debt/Equity (mrq)

    6.55%

  • Levered Free Cash Flow (ttm)

    21.31M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: